{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:28:47Z","timestamp":1788251327921,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:20:15Z","timestamp":1784546415000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A prospective observational study"],"prefix":"10.1016","author":[{"given":"Anne-Sophie","family":"Aubriot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Gon\u00e7alv\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7361-5118","authenticated-orcid":false,"given":"Laura","family":"Santel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1019","authenticated-orcid":false,"given":"Silvia","family":"Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Goubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-1150","authenticated-orcid":false,"given":"Gr\u00e9gory","family":"Reychler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-3382","authenticated-orcid":false,"given":"Morgane","family":"Penelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.07.003_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.07.003_bib0002","series-title":"Cystic fibrosis patient registry: 2017 annual data report","author":"Marshall","year":"2018"},{"issue":"10212","key":"10.1016\/j.jcf.2026.07.003_bib0003","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2026.07.003_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.003_bib0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1183\/09031936.00091607","article-title":"Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis","volume":"33","author":"Troosters","year":"2009","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.jcf.2026.07.003_bib0006","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1164\/rccm.201806-1110OC","article-title":"Cardiopulmonary exercise testing provides additional prognostic information in cystic fibrosis","volume":"199","author":"Hebestreit","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.07.003_bib0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2466-14-26","article-title":"Quality of life is associated with physical activity and fitness in cystic fibrosis","volume":"14","author":"Hebestreit","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"12","key":"10.1016\/j.jcf.2026.07.003_bib0008","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.4187\/respcare.04821","article-title":"The 1-minute sit-to-stand test in adults with cystic fibrosis: correlations with cardiopulmonary exercise test, 6-minute walk test, and quadriceps strength","volume":"61","author":"Gruet","year":"2016","journal-title":"Respir Care"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.003_bib0009","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jcf.2017.01.012","article-title":"The 1-min sit-to-stand test in cystic fibrosis - insights into cardiorespiratory responses","volume":"16","author":"Radtke","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"174","key":"10.1016\/j.jcf.2026.07.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0142-2024","article-title":"Clinimetric properties of field exercise tests in cystic fibrosis: a systematic review","volume":"33","author":"Corda","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.003_bib0011","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-022-02176-6","article-title":"One-minute sit-to-stand test is practical to assess and follow the muscle weakness in cystic fibrosis","volume":"23","author":"Hardy","year":"2022","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.jcf.2026.07.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26729","article-title":"One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis","volume":"10","author":"Anne-Sophie","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1183\/09031936.00150314","article-title":"An official European Respiratory Society\/American Thoracic Society technical standard: field walking tests in chronic respiratory disease","volume":"44","author":"Holland","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2026.07.003_bib0014","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/rccm.200607-883OC","article-title":"Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years","volume":"176","author":"Li","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"10.1016\/j.jcf.2026.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2026.07.003_bib0016","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.rmed.2006.01.001","article-title":"Reference values for the 6-min walk test in healthy subjects 20-50 years old","volume":"100","author":"Chetta","year":"2006","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.07.003_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049143","article-title":"Reference values and validation of the 1-minute sit-to-stand test in healthy 5-16-year-old youth: a cross-sectional study","volume":"11","author":"Haile","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.003_bib0018","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00038-013-0504-z","article-title":"Population-based reference values for the 1-min sit-to-stand test","volume":"58","author":"Strassmann","year":"2013","journal-title":"Int J Public Health"},{"issue":"8","key":"10.1016\/j.jcf.2026.07.003_bib0019","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.rmr.2013.10.645","article-title":"Maximal isometric voluntary quadriceps strength assessment in COPD]","volume":"31","author":"Bachasson","year":"2014","journal-title":"Rev Mal Respir"},{"issue":"7","key":"10.1016\/j.jcf.2026.07.003_bib0020","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/09593985.2011.640385","article-title":"Cram P. Isometric knee extension force measured using a handheld dynamometer with and without belt-stabilization","volume":"28","author":"Bohannon","year":"2012","journal-title":"Physiother Theory Pract"},{"issue":"10","key":"10.1016\/j.jcf.2026.07.003_bib0021","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.apmr.2007.07.011","article-title":"Development of a French isometric strength normative database for adults using quantitative muscle testing","volume":"88","author":"Hogrel","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jcf.2026.07.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108178","article-title":"Change in the 6-min walk test among 71 patients with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"244","author":"Perrone","year":"2025","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.07.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71044","article-title":"Peripheral muscle function and body composition in people with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor: a cross-sectional single-centre study","volume":"60","author":"Clayton","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"169","key":"10.1016\/j.jcf.2026.07.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2023","article-title":"Guidance and standard operating procedures for functional exercise testing in cystic fibrosis","volume":"32","author":"Saynor","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.jcf.2026.07.003_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcf.2015.08.006","article-title":"The 1-min sit-to-stand test\u2013A simple functional capacity test in cystic fibrosis?","volume":"15","author":"Radtke","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.07.003_bib0026","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2026.02.015","article-title":"Changes to serum lipids, BMI and body composition in adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor (ETI): a scoping review","volume":"25","author":"Walsh","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.07.003_bib0027","first-page":"241","volume":"23","author":"Sagel","year":"2026"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.003_bib0028","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.21982","article-title":"Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise","volume":"67","author":"Lamhonwah","year":"2010","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.jcf.2026.07.003_bib0029","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bbadis.2017.08.011","article-title":"Mechanisms of endothelial cell dysfunction in cystic fibrosis","volume":"1863","author":"Totani","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jcf.2026.07.003_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fspor.2024.1284878","article-title":"Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Gruber","year":"2024","journal-title":"Front Sports Act Living"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.003_bib0031","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2024.04.010","article-title":"Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment - a Danish prospective cohort","volume":"23","author":"Philipsen","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.003_bib0032","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2025.10.005","article-title":"Limited impact of Elexacaftor\/Tezacaftor\/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training","volume":"25","author":"Retucci","year":"2026","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2026.07.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71076","article-title":"Effects of an exercise intervention on exercise capacity in adults with cystic fibrosis: a quasi-experimental study comparing individuals treated with and without elexacaftor\/tezacaftor\/ivacaftor","volume":"60","author":"Gruber","year":"2025","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:54:08Z","timestamp":1784663648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S1569199326016577"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}